A multicenter phase II study in China is investigating its antitumor activity in terms of the ORR, DOR, DCR, and OS in advanced EGFR- and ALK-negative treatment-naive and ICI refractory PD-L1-positive NSCLC patients [111]. Here, ALK is linked to non-small cell lung carcinoma.